Editorial
Copyright ©The Author(s) 2022.
World J Hepatol. Jul 27, 2022; 14(7): 1269-1276
Published online Jul 27, 2022. doi: 10.4254/wjh.v14.i7.1269
Figure 1
Figure 1 Pathological changes of drug-induced liver injury -induced by atezolizumab used for treatment of hepatocellular carcinoma (H&E 40×). A: Portal inflammation and interfase hepatitis; B: Focal lobular necrosis; C: Frequent lobular acidophilic bodies; D: Ductal damage and migration of inflammatory cells into ductal epithelium; E: Hepatocyte rosettes as a result of liver regeneration; F: Hepatocanalicular cholestasis and biliary plugs.